知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

300 条记录 (耗时 0.039 秒)

    PREDICTION OF THE SUSCEPTIBILITY OF AN AT RISK PATIENT FOR DEVELOPING OR REDEVELOPING CLOSTRIDIUM DIFFICILE INFECTION
    193.
    发明申请
    PREDICTION OF THE SUSCEPTIBILITY OF AN AT RISK PATIENT FOR DEVELOPING OR REDEVELOPING CLOSTRIDIUM DIFFICILE INFECTION 审中-公开

    公开(公告)号：US20170242006A1

    公开(公告)日：2017-08-24

    申请号：US15519724

    申请日：2015-10-16

    申请人： BIOMERIEUX

    发明人： Agnès FOUSSADIER ,  Mark MILLER

    IPC分类号： G01N33/569

    CPC分类号： G01N33/56911 ,  G01N2333/33 ,  G01N2469/20 ,  G01N2800/54

    摘要： A method for prediction of the susceptibility of an at risk patient to developing or redeveloping an infection with Clostridium difficile, having the determination by immunoassay, in a stool sample from said patient, of the level of antibody IgA anti-toxin B of Clostridium difficile, and comparing this level with a reference value S determined beforehand using two populations of patients exposed to the bacterium, one population not having developed or redeveloped such an infection and the other population having developed or redeveloped such an infection, —a level lower than said reference value S signifying that the patient is a patient with a heightened risk of developing or redeveloping a Clostridium difficile infection, and —a level higher than said reference value S signifying that the patient is not a patient with a heightened risk of developing or redeveloping a Clostridium difficile infection.

    MIR-193A-3P and associated genes predict tumorigenesis and chemotherapy outcomes
    195.
    发明授权
    MIR-193A-3P and associated genes predict tumorigenesis and chemotherapy outcomes 有权
    MIR-193A-3P和相关基因预测肿瘤发生和化疗结果

    公开(公告)号：US09540698B2

    公开(公告)日：2017-01-10

    申请号：US14807647

    申请日：2015-07-23

    申请人： Genedia Biotech Co., Ltd.

    发明人： Jingde Zhu

    IPC分类号： G01N33/574 ,  C12Q1/68

    CPC分类号： C12Q1/6886 ,  A61K31/513 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57484 ,  G01N2800/52 ,  G01N2800/54

    摘要： The disclosure provides a correlation between the expression level of the miR-193a gene, which can be regulated by its methylation status, and both tumorigenesis of and the resistance of a cancer cell to a pyrimidine antimetabolite (5-FU) based chemotherapy. In addition to the methylation status and the expression of miR-193a, its downstream genes, such as E2F1, SRSF2, and apoptotic genes such as caspase 2, are also involved and can serve as useful markers for cancer therapy prognosis and for therapy selection.

    摘要翻译： 本公开提供了可以通过其甲基化状态调节的miR-193a基因的表达水平与癌细胞的肿瘤发生和抗细胞对基于嘧啶抗代谢药（5-FU）的化学疗法的抗性之间的相关性。 除了甲基化状态和miR-193a的表达外，其下游基因如E2F1，SRSF2和凋亡基因如半胱天冬酶2也有作用，可作为癌症治疗预后和治疗选择的有用标志物。

    Methods Predicting Risk of an Adverse Clinical Outcome
    196.
    发明申请
    Methods Predicting Risk of an Adverse Clinical Outcome 有权
    方法预测不良临床结局的风险

    公开(公告)号：US20160299153A1

    公开(公告)日：2016-10-13

    申请号：US14993196

    申请日：2016-01-12

    申请人： Critical Care Diagnostics, Inc.

    发明人： James V. Snider

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  C07K14/47 ,  C07K14/4726 ,  C07K14/715 ,  G01N33/53 ,  G01N33/68 ,  G01N33/6869 ,  G01N2333/4724 ,  G01N2333/7155 ,  G01N2800/32 ,  G01N2800/325 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/56

    摘要： Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 in a biological sample from the subject and determining a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the kit to evaluate the risk of an adverse clinical outcome in a subject, to decide whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis) or to initiate or terminate treatment, to select a subject for participation in a clinical study, and/or to select treatment for a subject.

    摘要翻译： 提供了评估受试者的不良临床结果的风险的方法，决定是否释放或继续治疗受试者（例如，以住院患者为对象），或开始或终止治疗，选择参与临床的受试者 研究和选择对受试者的治疗性治疗，其包括确定来自受试者的生物样品中的ST2水平，并确定来自受试者的生物样品中的半乳凝素-3的水平。 还提供了包含特异性结合ST2的抗体，特异性结合半乳聚糖-3的抗体的试剂盒，以及使用该试剂盒评估受试者的不良临床结果风险的指示，以决定是否释放或继续 治疗受试者（例如住院治疗）或开始或终止治疗，选择参与临床研究的受试者和/或选择对象的治疗。

    METHIONINE METABOLITES PREDICT AGGRESSIVE CANCER PROGRESSION
    200.
    发明申请
    METHIONINE METABOLITES PREDICT AGGRESSIVE CANCER PROGRESSION 审中-公开
    甲硫氨酸代谢物预防癌症进展

    公开(公告)号：US20150204882A1

    公开(公告)日：2015-07-23

    申请号：US14617016

    申请日：2015-02-09

    申请人： CEDARS-SINAI MEDICAL CENTER

    发明人： Neil A. Bhowmick ,  Diptiman Choudhury

    IPC分类号： G01N33/68 ,  G01N27/327 ,  C12Q1/00 ,  C12N9/88

    CPC分类号： G01N33/6815 ,  C12N9/88 ,  C12Q1/005 ,  C12Y402/01022 ,  C12Y404/01001 ,  G01N2333/90 ,  G01N2333/988 ,  G01N2800/54

    摘要： The invention relates to the use of enzymes, nanorods, and nanoelectronic devices to detect cysteine level in a patient sample and relates to the use of the detected cysteine level to predict cancer recurrence in the patient and to prescribe and/or administer an appropriate therapy to a subject. The invention is directed to systems and methods of detecting cysteine level in a sample from a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention further comprises prescribing and/or administering an appropriate therapy to a subject based on the predicted probability of recurrence.

    摘要翻译： 本发明涉及使用酶，纳米棒和纳米电子器件来检测患者样品中的半胱氨酸水平，并且涉及使用检测到的半胱氨酸水平来预测患者的癌症复发，并开出和/或施用适当的治疗方法 课程。 本发明涉及检测来自受试者的样品中的半胱氨酸水平的系统和方法，其中所述系统或方法还可包括测量至少一个附加参数，例如PSA水平，Gleason评分和临床分期。 本发明涉及预测受试者中癌症复发概率的系统和方法，其中所述系统或方法还可包括测量至少一个附加参数，例如PSA水平，Gleason评分和临床分期。 本发明还包括基于所预测的复发概率向受试者处方和/或施用适当的治疗。